Vaginal laser eased menopause symptoms in pooled trials

Genitourinary syndrome of menopause covers the vaginal dryness, painful sex and urinary symptoms that follow the fall in oestrogen, and it affects a large share of women for years rather than months. Topical hormonal treatments and lubricants are the mainstays, but some women cannot or prefer not to use hormones, which has created strong commercial interest in energy-based devices. Fractional CO2 laser is offered widely on that premise, often at considerable cost. Whether the randomised evidence actually supports it — and against which comparator — is the question this review addressed.

The authors systematically searched PubMed, Scopus, Web of Science, CINAHL, MEDLINE and ClinicalTrials.gov for randomised controlled trials in samples made up exclusively of women diagnosed with genitourinary syndrome of menopause. At least one group had to receive fractional CO2 laser, with control groups receiving simulated laser therapy, topical hormonal treatment or a topical gel lubricant, and studies had to report outcomes on sexual function, urinary symptoms or vaginal epithelium quality. Women with any history of cancer or previous treatment with a different type of laser were excluded. Two reviewers independently screened and extracted data, pooling differences in mean differences with 95% confidence intervals and using the I² statistic to gauge heterogeneity, across 11 included articles.

Pooled analysis indicated that fractional CO2 laser improved sexual function across several domains — desire, arousal, lubrication, orgasm and sexual satisfaction — and reduced pain during sexual activity, with a standardised mean difference of 0.51 (P = .021). Urinary function also improved, with reductions in the frequency and magnitude of urinary leakage and in how often women needed to urinate, at a standardised mean difference of 0.51 (P < .001). The one outcome that did not improve was the quality of the vaginal epithelium, despite that being the tissue change the treatment is meant to drive. The authors state plainly that the clinical significance of the observed changes is unclear.

This adds pooled randomised evidence to a field that has been dominated by uncontrolled case series and marketing, and it lands in a middle position: measurable symptom improvements, but no demonstrated change in the tissue outcome. The mismatch between symptom gains and unchanged epithelium quality is an open puzzle and raises the possibility of non-specific effects, which matters because controls variously received sham laser, hormonal cream or lubricant. Only short-term effectiveness was assessed, so nothing here speaks to how long any benefit lasts or how often treatment would need repeating. The exclusion of women with a cancer history also limits generalisability to a group often steered away from hormones.

If you are considering fractional CO2 laser for menopausal vaginal and urinary symptoms, this is a reason to think short-term symptom improvement is plausible rather than proven to be meaningful, since the reviewers could not establish clinical significance. The absence of any change in vaginal epithelium quality is worth knowing, because it undercuts the tissue-regeneration story often used to sell the procedure. Comparisons were against sham, hormonal treatment or lubricant, so the evidence does not establish that laser beats cheaper first-line options. Durability beyond the short term is simply unstudied here.